Question 1

Why do FDA and EMA requirements differ?

Accepted Answer

Despite ICH harmonization efforts, FDA and EMA maintain independent regulatory frameworks. Differences persist in areas like HVD bioequivalence (RSABE vs ABEL), NTI drug definitions, and pediatric study requirements (PREA vs PIP). These reflect different regulatory philosophies and legal mandates.

Question 2

What is ICH harmonization?

Accepted Answer

ICH (International Council for Harmonisation) develops harmonized guidelines accepted by FDA, EMA, and Health Canada. Successful examples include ICH M9 (BCS biowaivers), ICH E14 (QT assessment), and ICH M3 (nonclinical study timing). However, adoption and interpretation may vary.

Question 3

How do I design a study for both FDA and EMA?

Accepted Answer

Identify the most stringent requirement for each parameter. Design the study to satisfy all target agencies simultaneously. For bioequivalence, use a replicate crossover design and analyze with both RSABE (FDA) and ABEL (EMA) methods.

Question 4

Which agency is strictest for bioequivalence?

Accepted Answer

It depends on the context. FDA is strictest for NTI drugs (tightened limits). EMA caps HVD limits at 69.84-143.19% while FDA scales without cap. WHO does not accept any scaled approaches, making it strictest for HVD drugs.

Multi-Regulatory Comparison

You might also need